About this trial
The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:
What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?
What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?
Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.
Eligibility criteria
Qualifiers
Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria
Moderate-to-severe disease requiring systemic or advanced therapy
Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care
Evaluated in participating dermatology centers in Costa Rica
Disqualifiers
Lack of sufficient clinical data for severity or treatment assessment
Trial design
Treatments tested in this trial
- Abrocitinib
- Upadacitinib
- Baricitinib
- Dupilumab